Drug intelligence / Profile preview

TJ-AGC

Development stage: Preclinical
Lead developer: TJ Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TJ-AGC is a preclinical-stage antibody-steroid conjugate (also referred to as an antibody-glucocorticoid conjugate, or AGC) being developed by TJ Biopharma (formerly I-Mab Biopharma Hangzhou) for the treatment of autoimmune diseases. Built on the company's proprietary AntibodyPLUS platform, TJ-AGC is designed to deliver a potent glucocorticoid payload selectively to target cells, thereby maximizing the anti-inflammatory and immunosuppressive benefits of steroids while minimizing systemic side effects. The specific antibody target and payload identity have not been publicly disclosed.

Other names: TJ-AGC antibody-glucocorticoid conjugateTJ-AGC antibody-steroid conjugate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on TJ-AGC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ-AGC.

Explore the full profile